| 1. |
|
|
| 2. |
- Hollestelle, Antoinette, et al.
(författare)
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
- 2016
-
Ingår i: Gynecologic Oncology. - : Elsevier BV. - 0090-8258 .- 1095-6859. ; 141:2, s. 386-401
-
Tidskriftsartikel (refereegranskat)abstract
- Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Tilvi, V., et al.
(författare)
-
FIRST RESULTS FROM THE FAINT INFRARED GRISM SURVEY (FIGS) : FIRST SIMULTANEOUS DETECTION OF Ly alpha EMISSION AND LYMAN BREAK FROM A GALAXY AT z=7.51
- 2016
-
Ingår i: Astrophysical Journal Letters. - 2041-8205 .- 2041-8213. ; 827:1
-
Tidskriftsartikel (refereegranskat)abstract
- Galaxies at high redshifts are a valuable tool for studying cosmic dawn, therefore it is crucial to reliably identify these galaxies. Here, we present an unambiguous and first simultaneous detection of both the Ly alpha emission and the Lyman break from a z = 7.512 +/- 0.004 galaxy, observed in the Faint Infrared Grism Survey (FIGS). These spectra, taken with the G102 grism on the Hubble Space Telescope (HST), show a significant emission line detection (6 sigma) in two observational position angles (PAs), with Lya line flux of 1.06 +/- 0.19 x 10(-17) erg s(-1) cm(-2). The line flux is nearly a factor of four higher than that in the archival MOSFIRE spectroscopic observations. This is consistent with other recent observations, implying that ground-based near-infrared spectroscopy underestimates the total emission line fluxes, and if confirmed, can have strong implications for reionization studies that are based on ground-based Ly alpha measurements. A 4 sigma detection of the NV line in one PA also suggests a weak active galactic nucleus (AGN), and if confirmed, would make this source the highest-redshift AGN yet found. These observations from HST thus clearly demonstrate the sensitivity of the FIGS survey, and the capability of grism spectroscopy for studying the epoch of reionization.
|
|
| 6. |
- Faber, Zachary J, et al.
(författare)
-
The genomic landscape of core-binding factor acute myeloid leukemias
- 2016
-
Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 48, s. 1551-1556
-
Tidskriftsartikel (refereegranskat)abstract
- Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements involving the core-binding factor (CBF) transcriptional complex. To better understand the genomic landscape of CBF-AMLs, we analyzed both pediatric (n = 87) and adult (n = 78) samples, including cases with RUNX1-RUNX1T1 (n = 85) or CBFB-MYH11 (n = 80) rearrangements, by whole-genome or whole-exome sequencing. In addition to known mutations in the Ras pathway, we identified recurrent stabilizing mutations in CCND2, suggesting a previously unappreciated cooperating pathway in CBF-AML. Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex. This detailed analysis provides insights into the pathogenesis and development of CBF-AML, while highlighting dramatic differences in the landscapes of cooperating mutations for these related AML subtypes.
|
|
| 7. |
- Hanstock, Helen, 1989-, et al.
(författare)
-
Tear Fluid SIgA as a Noninvasive Biomarker of Mucosal Immunity and Common Cold Risk
- 2016
-
Ingår i: Medicine & Science in Sports & Exercise. - 0195-9131 .- 1530-0315. ; 48:3, s. 569-577
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: Research has not convincingly demonstrated the utility of saliva secretory Immunoglobulin-A (SIgA) as a biomarker of upper-respiratory-tract-infection (URTI) risk and disagreement exists about the influence of heavy exercise ('open-window-theory') and dehydration on saliva SIgA. Prompted by the search for viable alternatives, we compared the utility of tear and saliva SIgA to predict URTI prospectively (study-one) and assessed the influence of exercise (study-two) and dehydration (study-three) using a repeated-measures-crossover design.Methods: In study-one, forty subjects were recruited during the common-cold season. Subjects provided tear and saliva samples weekly and recorded upper-respiratory-symptoms (URS) daily for 3-weeks. RT-PCR confirmed common-cold pathogens in 9 of 11 subjects reporting URS (82%). Predictive utility of tear and saliva SIgA was explored by comparing healthy samples with those collected the week pre-URS. In study-two, thirteen subjects performed a 2-hour run at 65% VO2peak. In study-three, thirteen subjects performed exercise-heat-stress to 3% body-mass-loss followed by overnight fluid restriction.Results: Tear SIgA concentration and secretion rate were 48% and 51% lower respectively during URTI and 34% and 46% lower the week pre-URS (P<0.05) but saliva SIgA remained unchanged. URS risk the following week increased 9-fold (95% CI: 1.7 to 48) when tear SIgA secretion rate <5.5 μg[BULLET OPERATOR]min and 6-fold (95% CI: 1.2 to 29) when tear SIgA secretion rate decreased >30%. Tear SIgA secretion rate >5.5 μg[BULLET OPERATOR]min or no decrease >30% predicted subjects free of URS in >80% of cases. Tear SIgA concentration decreased post-exercise (-57%: P<0.05) in line with the 'open-window-theory' but was unaffected by dehydration. Saliva flow rate decreased and saliva SIgA concentration increased post-exercise and during dehydration (P<0.05).Conclusion: Tear SIgA has utility as a non-invasive biomarker of mucosal immunity and common-cold risk.
|
|
| 8. |
- Kristan, Matej, et al.
(författare)
-
The Visual Object Tracking VOT2016 Challenge Results
- 2016
-
Ingår i: COMPUTER VISION - ECCV 2016 WORKSHOPS, PT II. - Cham : SPRINGER INT PUBLISHING AG. - 9783319488813 - 9783319488806 ; , s. 777-823
-
Konferensbidrag (refereegranskat)abstract
- The Visual Object Tracking challenge VOT2016 aims at comparing short-term single-object visual trackers that do not apply pre-learned models of object appearance. Results of 70 trackers are presented, with a large number of trackers being published at major computer vision conferences and journals in the recent years. The number of tested state-of-the-art trackers makes the VOT 2016 the largest and most challenging benchmark on short-term tracking to date. For each participating tracker, a short description is provided in the Appendix. The VOT2016 goes beyond its predecessors by (i) introducing a new semi-automatic ground truth bounding box annotation methodology and (ii) extending the evaluation system with the no-reset experiment.
|
|
| 9. |
- Meulenbroek, O., et al.
(författare)
-
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease - The substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow
- 2016
-
Ingår i: BMJ Open. - : BMJ. - 2044-6055. ; 6:7
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: In conjunction with the NILVAD trial, a European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild-to-Moderate Alzheimer's disease (AD), there are four NILVAD substudies in which eligible NILVAD patients are also invited to participate. The main NILVAD protocol was previously published in BMJ Open (2014). The objectives of the NILVAD substudies are to determine whether frailty, cerebrospinal fluid (CSF), blood biomarker profile and Apolipoprotein E (APOE) status predict response to Nilvadipine, and to investigate the effect of Nilvadipine on cerebral blood flow and blood biomarkers. Methods and analysis: All participants who fulfil criteria for the main NILVAD study are eligible for participation in the NILVAD substudies. Participation is subject to informed consent and whether the substudy is available at a particular NILVAD study site. Each substudy entails extra measurements during the course of the main NILVAD study. For example, in the blood and genetic biomarkers substudy, extra blood (30 mL) will be collected at week 0, week 13, week 52 and week 78, while in the cerebral blood flow substudy, participants will receive an MRI and transcranial Doppler measurements at week 0, week 26 and week 78. In the CSF substudy, 10 mL CSF is collected at week 0 and week 78. Ethics and dissemination: All NILVAD substudies and all subsequent amendments have received ethical approval within each participating country, according to national regulations. Each participant provides written consent to participate. All participants remain anonymised throughout and the results of each substudy will be published in an international peer reviewed journal. © 2016 Published by the BMJ Publishing Group Limited.
|
|
| 10. |
- Robb, Magnus S., et al.
(författare)
-
The rediscovery of Strix butleri (Hume, 1878) in Oman and Iran, with molecular resolution of the identity of Strix omanensis Robb, van den Berg and Constantine, 2013
- 2016
-
Ingår i: Avian Research. - : Elsevier BV. - 2053-7166. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Many species of owls (Strigidae) represent cryptic species and their taxonomic study is in flux. In recent years, two new species of owls of the genus Strix have been described from the Middle East by different research teams. It has been suggested that one of these species, S. omanensis, is not a valid species but taxonomic comparisons have been hampered by the lack of voucher specimens of S. omanensis, and the poor state of the holotype of S. butleri. Methods: Here we use new DNA sequence data to clarify the taxonomy and nomenclature of the S. butleri complex. We also report the capture of a single S. butleri sensu stricto in Mashhad, Iran. Results: A cytochrome b sequence of S. omanensis was found to be identical to that of the holotype of S. butleri, indicating that the name S. omanensis is best regarded as a junior synonym of S. butleri. The identity of the S. butleri captured in Mashhad, Iran, was confirmed using DNA sequence data. This represents a major (1300 km) range extension of this species. Conclusions: The population discovered in Oman in 2013 and originally named 'S. omanensis' actually represents the rediscovery of S. butleri, which was known from a single specimen and had not been recorded since 1878. The range of S. butleri extends into northeast Iran. Our study augments the body of evidence for the recognition of S. butleri and S. hadorami as separate species and highlights the importance of using multiple evidence to study cryptic owl species.
|
|
